The funding will help drugmakers establish new production lines and facilities and expand fill and finish capacity.
“This $3 billion investment in our vaccine supply chain will create thousands of good-paying American jobs, help us deliver on the president’s commitment to be the arsenal of vaccines for the world, and strengthen our long-term capabilities to respond to future threats,” White House COVID-19 response coordinator Jeff Zients said.
The companies receiving the funding have not been selected yet, but the contracting process will “start across the next several weeks,” according to Mr. Zients.